Clinical Trials Browser

Interventional × Midazolam × 1 year × Clear all

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Phase 1/2 Active not recruiting

713 enrolled 1 FDA

Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

NCT07426757 2026-03-12

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Phase 1 Not yet recruiting

120 enrolled

Advanced Malignancies

NCT07408193 2026-02-20

The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.

Phase EARLY_PHASE1 Not yet recruiting

24 enrolled

Cancer Pain, Opioid-Related Disorders, Neoplasms

NCT04973163 2026-02-17

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Phase 1 Active not recruiting

30 enrolled

Other solid neoplasm

Solid Tumors, KRAS Mutation

NCT07235748 2026-02-17

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

Phase 1 Completed

28 enrolled

Healthy Adult Participants

NCT06575933 2026-02-11

MK-1084-009

Phase 1 Completed

28 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05646862 2026-02-05

INAVO121

Phase 3 Active not recruiting

420 enrolled

Breast

Breast Neoplasms

NCT05355701 2026-02-03

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Phase 1 Recruiting

267 enrolled

CNSDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

NCT02365597 2026-01-30

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Phase 2 Active not recruiting

239 enrolled 32 charts 1 FDA

Genitourinary

Urothelial Cancer

NCT07340190 2026-01-14

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

Phase 1 Not yet recruiting

24 enrolled

Advanced Malignancies

NCT04067336 2025-11-10

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Recruiting

263 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04543188 2025-10-23

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Phase 1 Terminated

65 enrolled 52 charts

CNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

NCT04557449 2025-10-01

CDK4i

Phase 2 Active not recruiting

362 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT06547164 2025-09-04

A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

Phase 1 Completed

40 enrolled

Breast

Breast Neoplasms

NCT04051827 2025-07-28

Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

26 enrolled 21 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06111872 2025-03-25

Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.

Phase 2 Completed

90 enrolled

Gastrointestinal

Cholangitis, Pancreatic Neoplasms, Choledochal Cyst, Choledocholithiasis